Advances in the Treatment of Colorectal Cancer: Targeting Receptors of Disease
作者： Wen Wee Ma , Antonio Jimeno , Michael A. Choti
DOI: 10.1007/978-1-60327-087-8_43
关键词:
摘要: The successful targeting of angiogenesis and epidermal growth factor receptor (EGFR) pathway has impacted the care advanced colorectal cancer (CRC) patients. Bevacizumab was first antiangiogenic agent to show survival benefit in first-line setting further trials suggested similar efficacy second-line maintenance settings. Cetuximab is an anti-EGFR monoclonal antibody that improved clinical outcomes for irinotecan-refractory CRC patients its role under investigation. Panitumumab a humanized shown improve treatment-refractory but failed achieve benefits setting. Current research effort therapy focuses on developing optimal approaches integrate these biological agents into care.
springer.com
sci-hub.st 参考文章(59)
Zhen Fan, Hideo Masui, John Mendelsohn, Jose Baselga, Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts Cancer Research. ,vol. 53, pp. 4637- 4642 ,(1993)
G Carpenter, S Cohen, Epidermal growth factor. Journal of Biological Chemistry. ,vol. 265, pp. 7709- 7712 ,(1972) , 10.1016/S0021-9258(19)38983-5
Rakesh K. Jain, Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine. ,vol. 7, pp. 987- 989 ,(2001) , 10.1038/NM0901-987
M A Poon, M J O'Connell, H S Wieand, J E Krook, J B Gerstner, L K Tschetter, R Levitt, C G Kardinal, J A Mailliard, Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. Journal of Clinical Oncology. ,vol. 9, pp. 1967- 1972 ,(1991) , 10.1200/JCO.1991.9.11.1967
C. Bokemeyer, I. Bondarenko, A. Makhson, J. T. Hartmann, J. Aparicio, M. Zampino, S. Donea, H. Ludwig, A. Zubel, P. Koralewski, Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer (mCRC): OPUS, a randomized phase II study Journal of Clinical Oncology. ,vol. 25, pp. 4035- 4035 ,(2007) , 10.1200/JCO.2007.25.18_SUPPL.4035
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
A de Gramont, J F Bosset, C Milan, P Rougier, O Bouché, P L Etienne, F Morvan, C Louvet, T Guillot, E François, L Bedenne, Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. Journal of Clinical Oncology. ,vol. 15, pp. 808- 815 ,(1997) , 10.1200/JCO.1997.15.2.808
D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R. Schilsky, R. Mayer, A. Venook, D. Niedzwiecki, Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results Journal of Clinical Oncology. ,vol. 24, pp. 3509- 3509 ,(2006) , 10.1200/JCO.2006.24.18_SUPPL.3509
T André, C Louvet, F Maindrault-Goebel, C Couteau, M Mabro, J.P Lotz, V Gilles-Amar, M Krulik, E Carola, V Izrael, A de Gramont, CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer European Journal of Cancer. ,vol. 35, pp. 1343- 1347 ,(1999) , 10.1016/S0959-8049(99)00150-1
David J. Kwiatkowski, Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biology & Therapy. ,vol. 2, pp. 471- 476 ,(2003) , 10.4161/CBT.2.5.446